"Fate has brought together the best minds in science with the top business minds in biotech," said Alex Rives, founding president of Fate. "Paul Grayson and John Mendlein are respected biotechnology executives with a history of developing breakthrough pharmaceuticals and innovative business strategies. Their leadership is the next step in creating an entirely new therapeutic paradigm for non-embryonic or adult stem cell medicine."
About Fate Therapeutics
Fate Therapeutics is a privately held biopharmaceutical company pioneering the field of renewal therapies, a newly emerging area of research and drug development. Founded by a world-class collaborative team of luminaries in the science of adult stem cell biology, management with a proven track record in translating new science into innovative drug and business opportunities, and an investor syndicate with an unparalleled history of establishing and advancing revolutionary biotechnology companies, Fate is working to launch a new era of medicine with the potential to offer new hope to patients afflicted with some of the most difficult to treat conditions, including degenerative diseases such as diabetes, Parkinson's and Alzheimer's Disease, ALS, heart failure, stroke and paralysis; developmental disorders including Down syndrome; and metastatic cancers.
For more information, see http://www.fatetherapeutic
|SOURCE Fate Therapeutics|
Copyright©2008 PR Newswire.
All rights reserved